Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1112)

## Matters in relation to an Administrative Investigation into a Subsidiary of the Group

The board of directors (the "Board") of Biostime International Holdings Limited (the "Company" and together with its subsidiaries, collectively referred to as the "Group") wishes to advise shareholders and potential investors of the Company of the following:

BiosTime, Inc. (Guangzhou) (廣州市合生元生物製品有限公司, "Biostime Guangzhou"), a wholly-owned subsidiary of the Company, is currently under an investigation (the "Investigation") conducted by National Development and Reform Commission of the People's Republic of China ("NDRC"). The main purpose of the Investigation is in relation to an alleged violation of Article 14 of Anti-Monopoly Law of the People's Republic of China by Biostime Guangzhou in managing the market sales prices at which the distributors and retail sales organizations sell our products.

As at the date of this announcement, the Investigation is still ongoing. The Company will actively cooperate with the Investigation and make further announcements to inform its shareholders of relevant updates when and where appropriate.

This announcement is made pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board

Biostime International Holdings Limited

Luo Fei

Chairman

Hong Kong, 27 June 2013

As at the date of this announcement, the executive Directors of the Company are Mr. Luo Fei and Ms. Kong Qingjuan; the non-executive Directors of the Company are Dr. Zhang Wenhui, Mr. Wu Xiong, Mr. Luo Yun and Mr. Chen Fufang; and the independent non-executive Directors of the Company are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.